Do Combination Sildenafil/Tadalafil ED Medications Make Any Sense

When used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies.

Tadalafil in Pregnancy

The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil tablets 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.In the placebo-controlled study, tadalafil sale the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by greater than or equal to 9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil. These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure.

When is 60 mg of tadalafil prescribed?

The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil without sexual activity. Others were reported to have occurred hours to days after the use of tadalafil and sexual activity. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors.Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitisNervous — Migraine, seizure and seizure recurrence, and transient global amnesiaOphthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)].Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended. Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil.

Product	Dosage	Quantity + Bonus	Price
Cialis Generic	10mg	10 Pills	31.41€ 29.91€	Buy
Tadalista Super Active	20mg	20 + 4 Pills	92.35€ 87.95€	Buy
Cialis Generic	5mg	30 + 4 Pills	53.56€ 51.01€	Buy
Cialis Generic	40mg	30 + 4 Pills	74.97€ 71.40€	Buy
Tadalista Super Active	20mg	180 + 20 Pills	521.59€ 496.75€	Buy
Cialis Generic	2.5mg	360 + 10 Pills	260.03€ 247.65€	Buy
Cialis Generic	20mg	360 + 10 Pills	427.34€ 406.99€	Buy
Cialis Generic	20mg	120 + 8 Pills	188.15€ 179.19€	Buy
Cialis Generic	10mg	20 Pills	48.23€ 45.93€	Buy
Cialis Generic	60mg	60 + 4 Pills	145.06€ 138.15€	Buy

It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)].

3. Competitive Pricing for Distributors & Importers

When mild vasodilators are taken in combination, blood pressure–lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil tablets can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. [See Clinical Pharmacology (12.2)].7.5 CYP3A Inhibitors/InducersRitonavirRitonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.4), and Clinical Pharmacology (12.3)].Potent Inhibitors of CYP3ATadalafil is metabolized predominantly by CYP3A in the liver. Tadalafil is also marketed for erectile dysfunction. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling:Hypotension [see Warnings and Precautions (5.1)]Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]Hearing loss [see Warnings and Precautions (5.4)]Priapism [see Warnings and Precautions (5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil tablets, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. The overall rates of discontinuation because of an adverse event (AE) in the placebo-controlled trial were 9% for tadalafil tablets 40 mg and 15% for placebo. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients.In the placebo-controlled study, tadalafil sale the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by greater than or equal to 9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo.6.2 Postmarketing ExperienceThe following adverse reactions have been identified during post-approval use of tadalafil. These events have been chosen for inclusion either because of their seriousness, reporting frequency, lack of clear alternative causation, or a combination of these factors.

• Tadalafil 40mg may require dose adjustments based on response.
• The medication can interact with blood thinners regarding bleeding risk.
• Regular health check-ups are recommended while using Tadalafil 40mg.
• Do not take Tadalafil 40mg if you are using recreational drugs.
• Women should not use Tadalafil 40mg, as safety in women is unestablished.
• Always inform your healthcare provider about all medications you are taking.

Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to estimate reliably their frequency or establish a causal relationship to drug exposure. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section.Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. Most, but not all, of these patients had preexisting cardiovascular risk factors. Many of these events were reported to occur during or shortly after sexual activity, and a few were reported to occur shortly after the use of tadalafil without sexual activity.

Population	Typical Dose Range	Notes
General adult males	20mg - 40mg	Adjust based on response and tolerance
Elderly	Usually lower dose	Due to potential liver and kidney function changes
Patients with hepatic impairment	Usually start at lower doses	Monitor response closely
Patients with renal impairment	Dose adjustment may be necessary	Depends on severity

Others were reported to have occurred hours to days after the use of tadalafil and sexual activity. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors.Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitisNervous — Migraine, seizure and seizure recurrence, and transient global amnesiaOphthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)].Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical tadalafil 2 5 mg follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.4) and Patient Counseling Information (17)].Urogenital — Priapism [see Warnings and Precautions (5.6)]. The following serious adverse reactions are discussed elsewhere in the labeling: Hypotension [see Warnings and Precautions (5.1)] Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)] Hearing loss [see Warnings and Precautions (5.4)] Priapism [see Warnings and Precautions (5.6)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Summary of Key Points

In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets[see Clinical Pharmacology (12.3)].Potent Inducers of CYP3AFor patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets[see Clinical Pharmacology (12.3)]. Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients. In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by greater than or equal to 9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo.

Uses of Tadalafil 40mg Tablets

In some of the cases, medical conditions and other factors were reported that may have also played a role in the otologic adverse events. In many cases, medical tadalafil 2 5 mg follow-up information was limited. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.4) and Patient Counseling Information (17)].Urogenital — Priapism [see Warnings and Precautions (5.6)]. The following serious adverse reactions are discussed elsewhere in the labeling: Hypotension [see Warnings and Precautions (5.1)] Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)] Hearing loss [see Warnings and Precautions (5.4)] Priapism [see Warnings and Precautions (5.6)] Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Tadalafil was administered to 398 patients with PAH during clinical trials worldwide.

Common Tadalafil Side Effects (Occurring in more than 1 in 10 people)

The rates of discontinuation because of AEs, other than those related to worsening of PAH, in patients treated with tadalafil tablets 40 mg was 4% compared to 5% in placebo-treated patients. In the placebo-controlled study, the most common AEs were generally transient and mild to moderate in intensity. Table 1 presents treatment-emergent adverse events reported by greater than or equal to 9% of patients in the tadalafil tablets 40 mg group and occurring more frequently than with placebo. The following adverse reactions have been identified during post-approval use of tadalafil. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section. The following adverse reactions have been identified during post-approval use of tadalafil. The list does not include adverse events that are reported from clinical trials and that are listed elsewhere in this section. Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors. Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitis Nervous — Migraine, seizure and seizure recurrence, and transient global amnesia Ophthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)].

• Tadalafil 40mg is effective for both erectile dysfunction and BPH symptoms.
• It is important to hydrate well when using this medication.
• Avoid grapefruit or grapefruit juice when taking Tadalafil 40mg.
• Do not use Tadalafil 40mg if you are allergic to similar medications.
• Monitor blood pressure regularly during Tadalafil therapy.
• Side effects tend to be mild but consult a doctor if severe.

Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.4) and Patient Counseling Information (17)]. Urogenital — Priapism [see Warnings and Precautions (5.6)]. 7 DRUG INTERACTIONS 7.1 NitratesAdministration of nitrates within 48 hours after the tadalafil over the counter uk last dose of tadalafil is contraindicated [see Contraindications (4.1)].7.2 Alpha-BlockersPDE5 inhibitors, including tadalafil tablets, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology (12.2)].7.3 AntihypertensivesPDE5 inhibitors, including tadalafil tablets, are mild systemic vasodilators.

About Pulmonary Arterial Hypertension (WHO Group 1)

When used to treat erectile dysfunction, non–arteritic anterior ischemic optic neuropathy (NAION), a cause of decreased vision, including permanent loss of vision, has been reported postmarketing in temporal association with the use of phosphodiesterase type 5 (PDE-5) inhibitors, including tadalafil. Other risk factors for NAION, such as the presence of “crowded” optic disc, may have contributed to the occurrence of NAION in these studies. Patients with known hereditary degenerative retinal disorders, including retinitis pigmentosa, were not included in the clinical trials, and use in these patients is not recommended. Cases of sudden decrease or loss of hearing, which may be accompanied by tinnitus and dizziness, have been reported in patients taking tadalafil. It is not possible to determine whether these events are related directly to the use of PDE5 inhibitors or to other factors [see Adverse Reactions (6.2)].

4. How important is being spontaneous?

Tadalafil is also marketed for erectile dysfunction. Inform patients taking tadalafil tablets not to take other PDE5 inhibitors. There have been reports of prolonged erections greater than 4 hours and priapism (painful erections greater than 6 hours in duration) for this class of compounds. 6 ADVERSE REACTIONS The following serious adverse reactions are discussed elsewhere in the labeling:Hypotension [see Warnings and Precautions (5.1)]Visual Loss [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]Hearing loss [see Warnings and Precautions (5.4)]Priapism [see Warnings and Precautions (5.6)]6.1 Clinical Trials ExperienceBecause clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.Tadalafil was administered to 398 patients with PAH during clinical trials worldwide. In trials of tadalafil tablets, a total of 311 and 251 subjects have been treated for at least 182 days and 360 days, respectively. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology (12.2)].7.4 AlcoholBoth alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. When mild vasodilators are taken in combination, blood pressure–lowering effects of each individual compound may be increased. Substantial consumption of alcohol (e.g., 5 units or greater) in combination with tadalafil tablets can increase the potential for orthostatic signs and symptoms, including increase in heart rate, decrease in standing blood pressure, dizziness, and headache. Tadalafil (10 mg or 20 mg) did not affect alcohol plasma concentrations and alcohol did not affect tadalafil plasma concentrations. [See Clinical Pharmacology (12.2)].7.5 CYP3A Inhibitors/InducersRitonavirRitonavir initially inhibits and later induces CYP3A, the enzyme involved in the metabolism of tadalafil. At steady state of ritonavir (about 1 week), the exposure to tadalafil is similar as in the absence of ritonavir [see Dosage and Administration (2.4), and Clinical Pharmacology (12.3)].Potent Inhibitors of CYP3ATadalafil is metabolized predominantly by CYP3A in the liver.

Tadalafil While Breastfeeding

Cardiovascular and cerebrovascular — Serious cardiovascular events, including myocardial infarction, sudden cardiac death, stroke, chest pain, palpitations, and tachycardia, have been reported postmarketing in temporal association with the use of tadalafil [see Contraindications (4.1)]. It is not possible to determine whether these events are related directly to tadalafil, to sexual activity, to the patient’s underlying cardiovascular disease, to a combination of these factors, or to other factors. Body as a whole — Hypersensitivity reactions including urticaria, Stevens–Johnson syndrome, and exfoliative dermatitis Nervous — Migraine, seizure and seizure recurrence, and transient global amnesia Ophthalmologic — Visual field defect, retinal vein occlusion, retinal artery occlusion, and NAION [see Warnings and Precautions (5.3) and Patient Counseling Information (17)]. Otologic — Cases of sudden decrease or loss of hearing have been reported postmarketing in temporal association with the use of PDE5 inhibitors, including tadalafil. It is not possible to determine whether these reported events are related directly to the use of tadalafil, to the patient’s underlying risk factors for hearing loss, a combination of these factors, or to other factors [see Warnings and Precautions (5.4) and Patient Counseling Information (17)].

How much tadalafil can you take daily?

Urogenital — Priapism [see Warnings and Precautions (5.6)]. 7 DRUG INTERACTIONS 7.1 NitratesAdministration of nitrates within 48 hours after the tadalafil over the counter uk last dose of tadalafil is contraindicated [see Contraindications (4.1)].7.2 Alpha-BlockersPDE5 inhibitors, including tadalafil tablets, and alpha–adrenergic blocking agents are both vasodilators with blood-pressure-lowering effects. When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. Clinical pharmacology studies have been conducted with coadministration of tadalafil with doxazosin, alfuzosin or tamsulosin [see Clinical Pharmacology (12.2)].7.3 AntihypertensivesPDE5 inhibitors, including tadalafil tablets, are mild systemic vasodilators. Small reductions in blood pressure occurred following coadministration of tadalafil with these agents compared with placebo [see Clinical Pharmacology (12.2)].7.4 AlcoholBoth alcohol and tadalafil, a PDE5 inhibitor, act as mild vasodilators. In patients taking potent inhibitors of CYP3A such as ketoconazole, and itraconazole, avoid use of tadalafil tablets[see Clinical Pharmacology (12.3)].Potent Inducers of CYP3AFor patients chronically taking potent inducers of CYP3A, such as rifampin, avoid use of tadalafil tablets[see Clinical Pharmacology (12.3)].